AF
KPTI icon

Amalgamated Financial’s Karyopharm Therapeutics KPTI Stock Holding History

Amalgamated Financial’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$86K Buy
+781
New +$97.3K ﹤0.01% 2203

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ITP
Iron Triangle Partners Cos Cob, Connecticut $875M AUM 49.85% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Amalgamated Financial's KPTI Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Karyopharm Therapeutics (KPTI) in Q1 2022: 781 shares worth $86K. The stake represents ﹤0.01% of the portfolio and ranks #2203 among its holdings.

139 funds tracked by Wall St. Rank hold KPTI as of Q1 2022.

  • Amalgamated Financial held 781 shares of Karyopharm Therapeutics worth $86K as of Q1 2022.
  • Karyopharm Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Karyopharm Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2203 holding.
  • 139 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.